In a long-awaited survey of employees at MD Anderson Cancer Center, faculty members show a significant drop in approval scores for the administration’s executive leadership, in comparison with the last time the survey was administered in 2012.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
